ArticleBMC microbiology2025
Bacillus cereus-derived α-amylase disrupts biofilm formation and quorum sensing in multidrug-resistant Klebsiella pneumoniae.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesKlebsiella pneumoniae is a multidrug-resistant pathogen implicated in severe community- and hospital-acquired infections such as bacteremia, urinary tract infections, sepsis, and pneumonia. Biofilm formation, driven by extracellular polymeric substances (EPS), enhances its persistence and resistance to antibiotics. This study evaluated the anti-biofilm, antibacterial, and quorum-quenching activities of a novel α-amylase B. cereus-derived α-amylase against clinical isolates of K. pneumoniae.
methodsThe anti-biofilm activity of the enzyme was assessed via minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC) assays. Biofilm architecture and viability were analyzed using confocal laser scanning microscopy (CLSM) with live/dead staining. Antibacterial efficacy was determined through minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. Quorum-quenching effects were evaluated using qRT-PCR to assess the expression of biofilm-associated genes (fimH and mrkD), normalized to rpoB.
resultsB. cereus-derived α-amylase exhibited MBIC and MBEC values of 64 µg/ml and 128 µg/ml, respectively; MIC and MBC ranged from 32 to 128 µg/ml. The B. cereus-derived α-amylase enzyme inhibited biofilm formation by approximately 79% ± 0.69, compared to 58% ± 2.06 by commercial α-amylase. Biofilm thickness was reduced from 179 μm to ~ 39 μm and ~ 73 μm following treatment with B. cereus-derived and commercial α-amylase, respectively. Live/dead ratios shifted significantly from 97/3% (untreated) to ~ 54/46% and 73/27% after treatment with B. cereus-derived and commercial α-amylase enzymes, respectively. Quorum-sensing gene expression was markedly downregulated following treatment with ½ MIC of B. cereus-derived α-amylase: fimH to 0.247 ± 0.045 (75.3% reduction) and mrkD to 0.187 ± 0.035 (81.3% reduction).
conclusionB. cereus-derived α-amylase exhibited potent anti-biofilm, antibacterial, and quorum-quenching activities against K. pneumoniae clinical isolates. These findings highlight its potential as a novel therapeutic agent for managing biofilm-associated infections, either alone or as an adjunct to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.